FIBER OPTIC FLUORESCENCE DETECTOR FOR PHOTOSENSITIZER

光敏剂光纤荧光检测器

• 批准号: 6513401
• 负责人: GREGORY C BURKE
• 金额: $ 34.88万
• 依托单位: AURORA OPTICS, INC.
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-09-30 至 2004-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6513401
• 关键词: Animalia; biomedical equipment development; blood chemistry; clinical research; fiber optics; fluorescence; fluorescence spectrometry; human subject; photosensitizing agents; radiation detector

DESCRIPTION: The efficacy and safety of photodynamic therapy (PDT) depends on an understanding of photosensitizer and light biology and dosimetry. Therefore, the ability to accurately determine photosensitizer levels in tumors and at-risk normal tissues is of utmost importance. The goal of this work is to develop and test a prototype system for fluorescence based measurement of photosensitizer uptake in tissue, to improve photodynamic therapy (PDT) dosimetry. The fiber optic system is designed to quantify photosensitizer concentration by detecting a fluorescence intensity signal which minimizes the impact of the tissue optical properties. The bundle is also designed to maximize the signal intensity, allowing quantitation of low concentrations of photosensitizers. Specialized designs have been developed for tissue surface measurement, interstitial measurement and sampling of drawn blood samples. The system is flexible enough to measure either porphyrin-based or phthalocyanine-based photosensitizers, and will specifically be tested in aminolevulinic acid-induced protoporphyrin IX (ALA - PpIX), Photofrin and aluminum disuiphonated phthalocynanine. The system design will be tested in three specific applications where PDT can be successfully commercialized, including (i) veterinary animal tumor therapy, (ii) research in experimental animal tumors, and (iii) adjuvant therapy for human brain tumors after resection. In order to successfully evaluate the system in these different PDT markets, prototype systems will be developed and tested in academic research labs at Dartmouth Medical School and the University of Toronto. The tests will (i) determine how robust the design is, (ii) determine if this dosimetry method improves PDT treatment outcome and (iii) demonstrate safety in human use, prior to commercial development. PROPOSED COMMERCIAL APPLICATION: Not Available

描述：光动力疗法 (PDT) 的功效和安全性取决于 了解光敏剂、光生物学和剂量测定。所以， 准确测定肿瘤中光敏剂水平的能力 有风险的正常组织至关重要。这项工作的目标是 开发并测试基于荧光的测量原型系统 组织吸收光敏剂，改善光动力疗法 (PDT) 剂量测定。光纤系统旨在量化光敏剂 通过检测荧光强度信号来最小化浓度 组织光学特性的影响。该捆绑包还旨在 最大化信号强度，允许低浓度的定量 光敏剂。针对组织表面开发了专门的设计 测量、间质测量和抽取血样取样。这 系统足够灵活，可以测量基于卟啉的或 酞菁基光敏剂，并将专门在 氨基乙酰丙酸诱导的原卟啉 IX (ALA - PpIX)、Photofrin 和 二磺酸酞菁铝。系统设计将在 PDT 可以成功商业化的三个具体应用， 包括（i）兽医动物肿瘤治疗，（ii）实验研究 动物肿瘤，以及（iii）人类脑肿瘤的辅助治疗 切除。为了在这些不同的 PDT 中成功评估系统 市场，原型系统将在学术研究中开发和测试 达特茅斯医学院和多伦多大学的实验室。测试将 (i) 确定设计的稳健性，(ii) 确定该剂量测定方法是否有效 改善 PDT 治疗结果，并且 (iii) 证明人类使用的安全性，事先 到商业发展。 拟议的商业应用： 无法使用